Acrivon Therapeutics, Inc.
ACRV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781174
In the last 90 days, Acrivon Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 46 institutions reported holding it in 13F filings for Q2 2026, worth $38.1M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Acrivon Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 39 | 40 | +1 |
| Shares | 15.2M | 15.1M | −89.7K (−0.6%) |
| Value | $191.1M | $196.0M | +$4.98M (+2.6%) |
New holders (5)
Institutions that held Acrivon Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Oconnor LLC | 100,000 | $1.30M | 0.03% |
| Nuveen Asset Management, LLC | 11,821 | $153.2K | 0.00% |
| Exchange Traded Concepts, LLC | 11,709 | $151.7K | 0.00% |
| AAFCPAs Wealth Management, LLC | 10,678 | $138.4K | 0.09% |
| Rhumbline Advisers | 8,986 | $116.5K | 0.00% |
Sold out (4)
Institutions that held Acrivon Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 32,262 | $409.4K |
| Goldman Sachs Group Inc | 13,718 | $174.1K |
| MetLife Investment Management | 5,081 | $64.5K |
| Metropolitan Life Insurance Co | 523 | $6.64K |